Articles tagged with: Kyprolis

News»

[ by | Jun 25, 2015 3:02 pm | 3 Comments ]
Multiple Myeloma Highlights From The 2015 ASCO, EHA, And IMWG Annual Summit Meetings

The annual meetings of the American Society of Clinical Oncology (ASCO) and the European Hematology Association (EHA) took place earlier this month. The two meetings were attended by tens of thousands of physi­cians from around the world, and featured a myriad of oral presentations, posters, and e-abstracts summarizing the results of new oncology- and hematology-related research.

Included in the research presented at the two meetings were more than 200 studies discussing new multiple myeloma-related findings.

In addition to the two large meetings held earlier this month, the Inter­na­tion­al Myeloma Working …

Read the full story »

News»

[ by | Jun 1, 2015 7:55 pm | 6 Comments ]
ASCO 2015 Multiple Myeloma Update – Poster Presentations: Current Therapies; Impact Of Del(17p) And T(11;14)

A poster session yesterday at the 2015 American Society of Clinical Oncology (ASCO) annual meeting was the venue for the first substantial dose of multiple myeloma-related presentations at the conference.

During the session, research results were made available for review by meeting attendees in the form of posters, each of which summarized the results of a single study. As is typically the case during such sessions, each poster was about two feet high by three or four feet in length. All posters were displayed throughout a large conference hall.

Most …

Read the full story »

News»

[ by | May 29, 2015 11:52 pm | 2 Comments ]
Latest Myeloma Research To Be Presented At The American Society Of Clinical Oncology Annual Meeting (ASCO 2015)

The 51st annual meeting of the American Society of Clinical Oncology (ASCO) started earlier today, May 29, and will go through June 2 in Chicago.

Approximately 30,000 physicians and researchers from all over the world are expected to attend the five-day meeting to discuss current research in cancer treat­ment and care.

During the meeting, there will be pre­sen­ta­tions about all types of cancer, in­clud­ing many pre­sen­ta­tions focused specifically on multiple myeloma. In fact, more than 90 myeloma-related studies are scheduled to be pre­sented, in one form or another, in connection …

Read the full story »

News»

[ by | Apr 7, 2015 6:43 pm | One Comment ]
Combination Of Farydak And High-Dose Kyprolis Effective In Relapsed Multiple Myeloma

The results of a small Phase 1/2 clinical trial suggest that a com­bi­na­tion of Farydak and high-dose Kyprolis is effective as a treat­ment for relapsed multiple myeloma.

Participants in the trial were heavily pretreated, having had a median of five previous myeloma ther­a­pies. More than 70 per­cent of the patients, however, had at least a partial re­sponse to the trial regi­men at the target doses established during the trial’s first phase. The estimated two-year overall survival rate among the patients was 67 percent.

A response rate of more than 70 …

Read the full story »

Deutsch»

[ by | Mar 10, 2015 4:33 pm | Comments Off ]
Hochdosiertes Kyprolis verlängert progressionsfreies Überleben gegenüber Velcade in randomisierter Vergleichsstudie für rezidivierte Myelompatienten

Erste Ergebnisse einer großen, direkten, klinischen Vergleichsstudie zeigen, dass rezidivierte Myelompatienten, die mit hochdosiertem Kyprolis und Dexamethason behandelt wurden, ein doppelt so langes progressionsfreies Überleben hatten im Vergleich zu rezidivierten Patienten, die mit Velcade und Dexamethason behandelt wurden.

Das mittlere progressionsfreie Überleben in der Phase 3-Studie betrug 18,7 Monate bei den mit hoch dosiertem Kyprolis (Carfilzomib) und Dexamethason behandelten Studienteilnehmern im Vergleich zu 9,4 Monaten bei Patienten, die Velcade (Bortezomib) und Dexamethason erhielten.

Die Ergebnisse der so genannten "ENDEAVOR"-Studie wurden am letzten Sonntagabend in einer von Amgen (NASDAQ:AMGN) herausgegebenen Presseinformation …

Read the full story »